Malignant Reproductive System Neoplasm — Research

Malignant Reproductive System Neoplasm — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	39	`("Malignant Reproductive System Neoplasm"[tiab] OR "Reproductive System Cancer"[tiab] OR "Cancer of Reproductive System"[tiab] OR "Cancer of the Reproductive System"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	21	`("Malignant Reproductive System Neoplasm"[tiab] OR "Reproductive System Cancer"[tiab] OR "Cancer of Reproductive System"[tiab] OR "Cancer of the Reproductive System"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	3	`("Malignant Reproductive System Neoplasm"[tiab] OR "Reproductive System Cancer"[tiab] OR "Cancer of Reproductive System"[tiab] OR "Cancer of the Reproductive System"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (605)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 551–575 of 605 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
· Cancer Cell · 2010 · PMID 20227043 · validated civic_curation pubmed
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
· Cancer Res · 2015 · PMID 25968887 · validated civic_curation pubmed
Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
· Clin Cancer Res · 2012 · PMID 22623731 · validated civic_curation pubmed
Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.